严重急性呼吸综合征后骨坏死的血液学改变及相关基因检测

目的探讨严重急性呼吸综合征(SARS)后骨坏死的病因学,以便用于非创伤性骨坏死的早期诊断和易感人群的筛选。方法取61例SARS后骨坏死患者空腹肘静脉血。另取健康人群52名为对照,应用酶联免疫吸附法等试验定凝血、纤溶指标,应用实时聚合酶链反应(PCR)仪测定因子V G1691A(FV Le iden)变、凝血酶原G20210A突变。结果SARS后骨坏死患者血液学因素改变明显,其中蛋白C(PC)、活化蛋白C抵抗(APC-R)、抗凝血酶Ⅲ(AT-Ⅲ)、纤溶酶原激活抑制物(PAI)、纤溶酶原(PLG)。两组比较,差异有统计学意义(109%±20%vs 85%±34%、8.0 U/m l±4.3U/m l、16 U/m l±14 U/m l、197 s±46 s vs 192 s±63 s、104%±14%vs 84%±29%、94%±15%vs69μ/m l±23μ/m l,P<0.01)。骨坏死组和对照组均未发现因子V Le iden突变和凝血酶原G20210A的突变。结论SARS后骨坏死患者存在高凝低纤溶倾向,对骨坏死易感人群可以进行高凝和低纤溶指标的筛选,PC、AT-Ⅲ、PAI、APC-R、PLG可作为骨坏死易感因素的筛选指标。SARS后骨坏死与因子V Le iden和凝血酶原G20210A突变无关。

Hematological changes and related gene mutation of post-severe acute respiratory syndrome patients with osteonecrosis

OBJECTIVE: To investigate the hematological changes and related gene mutation of post-severe acute respiratory syndrome (SARS) patients with osteonecrosis so as to find the sensitive molecular symbols for early screening of the high risk populations. METHODS: Fast peripheral venous blood samples were collected from 61 post-SARS patients with osteonecrosis, 25 males and 36 females, aged 30.4 (20 - 60), and 52 sex and age-matched healthy persons as controls. ELISA was used to detect the coagulation and fibrinolysis indicators: activated partial thromboplastin time (APTT), protein C (PC), antithrombin III (AT-III), plasminogen activator inhibitor (PAI), activated protein C resistance (APC-R), plasminogen (PLG), von Willebrand factor (VWF), D-dimer (D-D), and fibrinogen (Fib). Real-time PCR was used to detect the mutation of factor V G1601A (FV Leiden) and prothrombin G20210A. RESULTS: The levels of PC, AT-III, and PLG of the osteonecrosis group were 85% +/- 34%, 84 +/- 29%, and 69 +/- 23%, significantly lower than that of the control group (109% +/- 20%, 104% +/- 14%, and 94% +/- 15% respectively, all P < 0.01). PAI of the osteonecrosis group was 16 U/ml +/- 14 U/ml, significantly higher than that of the control group (8.0 U/ml +/- 4.3 U/ml, P < 0.01). The percentage of patients with abnormal indicators was 99.5% (54/61) in the osteonecrosis group, significantly higher than that of the control group (36.5%, 19/52, P < 0.01). The percentage of patients with 3 or more abnormal indicators was 72.1% (44/61) in the osteonecrosis group, significantly higher than that of the control group (17.3%, 9/52, P < 0.01). No mutations of F V Leiden and prothrombin G20210A was found in both groups. CONCLUSION: Trends of hypercoagulation and hypofibrinolysis exist in the post-SARS patients with osteonecrosis. APTT, PC, AT-III, and PLG can be used as sensitive indicator for screening high risk populations of osteonecrosis.